1xbet 모바일

1xbet 모바일s

January 5, 2012

Mu1xbet 모바일sta^®ophthalmic suspension UD2% releases on January 5, 2012

1xbet 모바일 (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced the launch of Mucosta ophthalmic suspension UD 2% for patients with dry eye diagnosed on January 5, 2012 in Japan.

Latest 1xbet 모바일 Business related News Releases

30 SEP 2024

HemeSight^®, the First-in-Japan 1xbet 모바일mprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight^®hematological malignancies gene panel test approved in Japan -

24 SEP 2024

1xbet 모바일 Obtains Additional Indication for Rexulti^®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease

1xbet 보너스 코드

1xbet 모바일 Receives Approval in Japan for Lupkynis^®as a Treatment for Lupus Nephritis

News Releases | Otsuka

1xbet 모바일

Mu1xbet 모바일sta®ophthalmic suspension UD2% releases on January 5, 2012

HemeSight®, the First-in-Japan 1xbet 모바일mprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight®hematological malignancies gene panel test approved in Japan -

1xbet 모바일 Obtains Additional Indication for Rexulti®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease

1xbet 모바일 Receives Approval in Japan for Lupkynis®as a Treatment for Lupus Nephritis

Mu1xbet 모바일sta^®ophthalmic suspension UD2% releases on January 5, 2012

HemeSight^®, the First-in-Japan 1xbet 모바일mprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight^®hematological malignancies gene panel test approved in Japan -

1xbet 모바일 Obtains Additional Indication for Rexulti^®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease

1xbet 모바일 Receives Approval in Japan for Lupkynis^®as a Treatment for Lupus Nephritis